Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (August 2023)
16 slides from Evofem Biosciences's investor presentation, Aug 28, 2023
Slide 1: Non-Hormonal Contraceptive Gel
NON-HORMONAL CONTRACEPTIVE GEL SAUNDRA PELLETIER CHIEF EXECUTIVE OFFICER AUGUST 25, 2023 E¥OFEM BIOSCIENCES aoa! orcas: evem SCIENCE WITH A SOUL
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS forward looking statements by terms such as "may," “will,” “should,” “expect,” "plan," “aim,” "anticipate," “strategy,” “objective,” “designed,” “suggest,” “currently,” “could,” "intend," "target, ‘leks and vncertainties. Actual results may differ materially from those, ex
Slide 3: 43.3 Million Potential Phexxi Users in the U.S.
43.3 MILLION POTENTIAL PHEXXI USERS IN THE U.S. (1) U.S. MARKET BY CONTRACEPTIVE METHOD (in retutons) $8.3 BILLION 20.0 M WOMEN USE PRESCRIPTION CONTRACEPTIVES (U.S. 2022)Q2 98 IUDs /eopper IUD study predates commercial availability of Phexxt al CONTRACEPTIVE _ MARKET. i susust 25, 2022 orcas: evem
Slide 4: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION With innovative women’s reproductive and sexual health solutions THE FIRST AND ONLY ON-DEMAND, NON-HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL \ + Vaginal pH Modulator 1 + Hormone-free + FDA-approved for prevention of pregnancy + Woman-controlled + Used only when
Slide 5: MOA - Phexxi Is a pH Modulator
MOA - PHEXXI IS A pH MODULATOR Optimal vaginal pH levels can range from 3.5 — 4.5 WHEN SEMEN (pH 7.1-8) ENTERS THE VAGINA, IT RAISES THE ENVIRONMENTAL pH LEVEL ALLOWS SPERM TO BE MOBILE AND SWIM UP THE REPRODUCTIVE CANAL PHEXXI KEEPS VAGINAL pH IN THE OPTIMAL RANGE susust 25, 2022 orcas: evEM
Slide 6: Every 1% Market Share of the 43.3 Million Women in Our Addressable Market
fe yi. EVERY 1% MARKET SHARE OF THE 43.3 MILLION WOMEN IN OUR ? er ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES Phexxi Boxes per Woman per year | GROSS WAC: $338.10 (1) aes PER BOX OF 12 PHEXX! APPLICATORS = | PAID BY THE PLAN, NOT THE WOMAN. Ne UNOER FEDERAL Law, MosY PAYERS Aust coo
Slide 7: On track to achieve third consecutive year of revenue growth in FY 2023
On track to achieve third consecutive year of revenue growth in FY 2023 phen NET PRODUCT SALES GROWTH SINCE LAUNCH om $16.8 IN MILLIONS sa 2020, 14 2023 orcas evem
Slide 8: Activating Select Patient Types to Use Phexxi
ACTIVATING SELECT PATIENT TYPES TO USE PHEXXI Targeting women who are aligned with the current Phexxi user profiles Capitalizing on where Phexxi is already performing NON-HORMONAL sucust 25, 2022 orcas: evem
Slide 9: Activating Phexxi Utilization with Select Patient Types
ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES Prior Contraception Among Women Switching to Phexxi! | 80.6% WERE NOT ON ANY METHOD OF Rx CONTRACEPTION | 9.9% SWITCHING FROM ORAL CONTRACEPTIVE | 1.7% SWITCHING FROM HORMONAL RINGS AND PATCHES WE ARE SUCCESSFULLY REACHING OUR TARGET PATIENT TY
Slide 10: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal BIRTH CONTROL IS PERSONAL. HORMONE HOR WHICH METHOD" MEETS Your NEEDS? CONTAINS. HORMONES un susust 25, 2022 orcas: evem
Slide 11: Territory Optimization Aligns with Strategic Imperatives
TERRITORY OPTIMIZATION ALIGNS WITH STRATEGIC IMPERATIVES Targeting HCPs with an abundance of the Phexxi patient type . ee SALES LEADERSHIP — 4 1 Vice President, Sales 3 Regional Business Managers SALES TEAM - 16 The "white space" is divided amongst the 16 representatives to maximize all opportunitie
Slide 12: U.S. Government Clarifies Contraceptive Access
U -S. GOVERNMENT CLARIFIES CONTRACEPTIVE ACCESS Updated guidelines took effect January 1, 2023, for calendar year plans “UNDER THE ACA, MOST PRIVATE HEALTH PLANS ARE REQUIRED TO PROVIDE BIRTH CONTROL... AT NO ADDITIONAL COST.” -- U.S. Departments of Health and Human Services, Labor and the Treasury,
Slide 13: Increasing Phexxi Access Through Payer Wins
INCREASING PHEXXI ACCESS THROUGH PAYER WINS YTD 2023 Evofem has gained Phexxi coverage for more than 22.1M new lives EFFECTIVE ERR POSITION Colorado Medicaid Oct, 2, 2023, Nya Indiana State Medicaid Preferred Agent on Indiana Statewide Uniform Medicaid POL Jan. 2, 2023 Vv Vv Nia Preferred with no PA
Slide 14: U.S. Intellectual Property Protects Phexxi into at Least 2033
15 U.S. INTELLECTUAL PROPERTY PROTECTS PHEXXI INTO AT LEAST 2033 FOUR ORANGE BOOK LISTED PATENTS 11,337,989 : Method of use patent covering contraception using the L-Lactic Acid Phexxi formulation + Expected to provide protection into at least March 2033 + 11,439,610: Composition of matter patent co
Slide 15: Why Evofem? Why Now?
16 WHY EVOFEM? WHY NOW? SHATTERING THE HORMONE GLASS CEILING WITH FIRST-IN-CLASS PRODUCT + Hormone-free FDA-approved contraceptive that is woman-controlled and used only when needed * Intellectual Property protection into at least 2033 ATTRACTIVE TARGET MARKET * Asmall percentage of market share yie
Slide 16: Thank You
THANK YOU EYOFEM BIOSCIENCES
Evofem Biosciences — Investor Presentation (August 2023) on 6ix